Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.49 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
| ▸ | ITK | Q08881 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.38 |
| ▸ | CHRNG | P07510 | 1/20 | 0.38 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4504163 | 0.89 | LCK (0.52) | BTKTNK2LCKJAK3ITK | |
| SCHEMBL4496267 | 0.88 | LCK (0.47) | BTKTNK2LCKJAK3ITK | |
| SCHEMBL4495790 | 0.87 | LCK (0.57) | BTKTNK2LCKJAK3ITK | |
| SCHEMBL4504866 | 0.85 | LCK (0.48) | BTKTNK2LCKJAK3ITK | |
| SCHEMBL4507796 | 0.79 | SRC (0.60) | BTKTNK2LCKJAK3MAPK1 | |
| SCHEMBL4486167 | 0.78 | LCK (0.61) | BTKTNK2LCKJAK3ITK | |
| SCHEMBL4494221 | 0.78 | LCK (0.60) | BTKTNK2LCKJAK3ITK | |
| SCHEMBL4500405 | 0.78 | LCK (0.60) | BTKTNK2LCKJAK3ITK | |
| SCHEMBL4491697 | 0.77 | JAK3 (0.57) | BTKTNK2LCKJAK3KCNH2 | |
| SCHEMBL4489739 | 0.77 | LCK (0.51) | BTKTNK2LCKJAK3ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | claimed |
| US-7504396-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | ICOS, CD4, HLA-DRB1 | BTK 1420/4885TNK2 1854/4885LCK 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.